

Supplementary Figure 1. Hematoxylin and eosin (H&E) stain and trichrome stain of representative 7-week-old *KIC* tumor.



Supplementary Figure 2. Axl gene expression in pancreatic cancer patient-derived xenografts (PDX). RNA isolated from baseline (untreated) tumors was profiled using Affymetrix U133 Plus 2.0 gene arrays.



Supplementary Figure 3. Pan02 tumor tissue from mice treated as described in Figure 2 was evaluated by immunofluorescence for cleaved-caspase 3, phospho-histone-3, endomucin, E-cadherin, and vimentin. Images were analyzed using Elements software; quantification of % area fraction is shown. Data are displayed as mean ± SD and represent 5 images per tumor with 4 animals per group analyzed. **P* < 0.05; ****P* < 0.005; *****P* < 0.001; by ANOVA with Tukey's MCT.



Supplementary Figure 4. Tumor lysates from *KIC* animals with 2-week treatment of BGB324 (50 mg/kg PO BID, or vehicle (Cntl) were probed for the level of active TBK1 and NF-kB by Western blotting for the indicated targets.



Supplementary Figure 5. Pan02 pancreatic tissue was stained for F4/80. Images were analyzed using Elements software; quantification of % area fraction is shown. Data are displayed as mean ± SD and represent 5 images per tumor with 4 animals per group analyzed. *$P < 0.05$; ****$P < 0.001$; by ANOVA with Tukey's MCT.



Supplementary Figure 6. The mRNA expression level of Arginase 1 was determined by q-PCR in control, IL-4, and IL-4 + BGB324-treated bone marrow-derived macrophages. Bone marrow-derived macrophages were isolated from C57BL/6J mice and stimulated with control (0.02% DMSO in media), IL-4 (40 ng/ml), or IL-4 (40 ng/ml) + BGB324 (2 μM) for 18 hours.



Supplementary Figure 7. Flow cytometry of KPC-M09 subcutaneous tumors treated with vehicle (control) or BGB324 (50 mg/kg, PO, BID) for two weeks as described in the supplementary methods. BGB324 didn't alter CD11b+ cells PMN-MDSCs ($CD11b^+$ $Ly6G^+$ $Ly6C^+$), and PD-$L1^+$ PMN-MDSCs,

Supplementary Table 1: Cytokine/Chemokine Concentration (pg/ml) in *KIC* tumor lysates from different treatment groups

	Cntl	Gem	BGB	Combo
G-CSF	394	196.68	167	298.5
GM-CSF	261.5	330	232.5	273.5
IFNγ	61.025	69.78	47.655	43.615
IL-1α	289.5	309	228.5	217.5
IL-2	20.98	21.035	17.345	25.145
IL-3	3.85	2.46	1.58	1.375
IL-4	3.565	1.84	1.725	1.655
IL-5	8.515	5.66	4.945	2.23
IL-9	1361	579	880.5	1314
IL-10	29.44	12.68	28.84	13.055
IL-12_p40	203.5	158	145	141
IL-12_p70	20.345	0	3.96	1.995
IL-13	15.1	3.48	0	0
IL-15	50.91	21.29	18.12	20.835
IL-17	14.42	7.02	6.555	9.03
IP-10	48.005	105.06	32.36	30.88
KC	270	283	131.93	228.5
LIF	182	285	150.5	133.5
LIX	34.815	1.74	0	0
MCP-1	319.5	257	185.29	135.5
M-CSF	25.37	10.97	12.275	8.225
MIG	66.38	60.73	13.85	27.085
MIP-1α	45.825	26.54	15.55	12.22
MIP-1β	12.43	33.27	3.49	0
MIP-2	309.5	89.44	120.16	30.625
RANTES	7.72	6.99	1.915	2.465
TNF-α	11.135	5.835	7.855	4.945
VEGF	13.015	85.99	9.8	265.5

Supplementary Table 1. The concentration of cytokines and chemokines in *KIC* tumor lysates were tested by MILLIPLEX (Immunology Multiplex Assay, Millipore).